Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001701541-20-000018
Filing Date
2020-05-12
Accepted
2020-05-12 07:34:10
Documents
61
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q bdtx-20200331.htm   iXBRL 10-Q 1461894
2 EX-31.1 exhibit311q12020.htm EX-31.1 15150
3 EX-31.2 exhibit312q12020.htm EX-31.2 14944
4 EX-32.1 exhibit321q12020.htm EX-32.1 13458
  Complete submission text file 0001701541-20-000018.txt   4708760

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bdtx-20200331.xsd EX-101.SCH 27323
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT bdtx-20200331_cal.xml EX-101.CAL 60113
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT bdtx-20200331_def.xml EX-101.DEF 111561
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bdtx-20200331_lab.xml EX-101.LAB 360041
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bdtx-20200331_pre.xml EX-101.PRE 231543
17 EXTRACTED XBRL INSTANCE DOCUMENT bdtx-20200331_htm.xml XML 592421
Mailing Address 139 MAIN STREET CAMBRIDGE MA 02142
Business Address 139 MAIN STREET CAMBRIDGE MA 02142 617-417-5868
Black Diamond Therapeutics, Inc. (Filer) CIK: 0001701541 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39200 | Film No.: 20867047
SIC: 2836 Biological Products, (No Diagnostic Substances)